Enveric Biosciences Inc recorded a cumulative net loss of $-9 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 276 other companies achieving higher income per employee. While Enveric Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 3683 to 3811.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ENVB Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,454,841	-1,370,082	-1,461,998	-1,622,077	-1,657,138
ENVB's Total Ranking	# 3811	# 3683	# 3645	# 3393	# 3142
Seq. Net Income Change	-	-	-	-	-

ENVB Company Profile >> Back to ENVB Efficiency Comparisons >> Compare ENVB Net Income per Employee to its Competitors

ENVB Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 277
Healthcare Sector	# 678
Overall Market	# 3811

Net Income per Employee Statistics
High	Average	Low
$ 397,859	$ -2,306,459	$ -8,690,037
(Sep 30 2018)		(Jun 30 2022)

News about Enveric Biosciences Inc Income per employee

Enveric Biosciences Achieves Preclinical Success with EB-003 Amid Financial Pressures,

Enveric Biosciences Advances with EB-003 Amidst Financial Challenges Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company based in Cambridge, Massachusetts, is making strides in the realm of neuropsychiatric therapeutic development. Recently, the company announced a significant advancement with its lead candidate, EB-003, which targets neuropsychiatric indications such as depression and post-traumatic stress disorder (PTSD). The company revealed the successful completion of 7-day Dose Range Finding (DRF) toxicology studies in two preclinical species. These studies are pivotal, defining the maximum tolerated dose, a critical step towards gaining approval for more advanced clinical trials.The news of these successful preclinical studies marks a promising milestone for Enveric, which aims to bring novel neuroplastogenic small-molecule therapeutics to the market. This class of drugs shows potential in restoring neuronal plasticity, which could lead to new treatment paradigms for a variety of neuropsychiatric disorders that currently have limited therapeutic options. As the company progresses, the focus remains on further evaluating EB-003 s safety and efficacy to strengthen its case for an Investigational New Drug (IND) application with the FDA.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-08-15T21:22:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.